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INTRODUCTION
Lower urinary tract symptoms due to benign prostatic
hyperplasia (BPH/LUTS) and benign prostatic enlarge-
ment are very common diseases in men older than 40
years (1). Male sexual dysfunction are, also, very common
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Objective. The relationship between lower urinary tract symptoms (LUTS) and erectile
dysfunction (ED) has recently received increased attention. The aim of this study was to
evaluate the efficacy of the Alfa-5® association of Serenoa repens, Pinus massoniana
Bark Extract (PMBE) and Crocus sativus (IDIProst® Gold) in improvement of patient’s
quality of life, when compared with Serenoa repens alone.
Materials and Methods. All patients with clinical and instrumental diagnosis of LUTS due to
Benign Prostatic Hyperplasia (BPH) and ED, attending 5 Italians Urological Institutions from
May to December 2012 were enrolled in this prospective, multicentre, phase 3 study. 
Participants were assigned to receive oral capsules of IDIProst® Gold (one capsule q24 h) or
Serenoa repens 320 mg (one capsule q24h) for 3 months. Clinical and instrumental analyses
were carried out at the enrolment and at the end of therapy. IPSS, IIEF-5 and SF-36 question-
naires have been used. The main outcome measure was the improvement of quality of life at the
end of the whole study period.
Results. 129 (mean age 45-71 ± 4.36) men were randomly allocated to IDIProst® Gold (n = 83)
or Serenoa repens (n = 46). The baseline questionnaire mean scores were 17.1 ± 6.4, 14.9 ± 3.7,
96.3 ± 1.2 for IPSS, IIEF-5 and SF-36, respectively. At the follow-up examination, statistically
 significant differences have been reported in terms of IPSS (11.9 vs 13.8; p < 0.001), IIEF-5 and
SF-36 mean scores (19.3 vs 16.1; 99.7 vs 96.3; p < 0.003; p < 0.001). Moreover, statistically
 significant differences were then reported between the two visits, in terms of IPSS, IIEF-5 and  
SF-36 scores (p < 0.003; p < 0.001; p < 0.001), only in the IDIProst® Gold group.
Conclusions. In conclusions, we found that IDIProst® Gold significantly improve the quality of life
of patients affected by LUTS due to BPH and ED, specifically in terms of sexual function, high-
lighting that a better sexual quality of life is correlated with an higher overall quality of life
regardless of the urinary function.
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Summary
in this population; in the European Male Ageing Study of
3,369 community-dwelling men aged 40-79 years, mod-
erate or severe erectile dysfunction (ED) was reported by
6% of men in their forties, rising to 64% of men aged over
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70 years (2). Moreover, in the Multinational Survey of the
Ageing Male (MSAM-7) the overall prevalence of LUTS was
90%, while the overall prevalence of ED was 49%, high-
lighting that rate of ED was significantly dependent on age
and correlated highly with the severity of LUTS (3). Both
BPH⁄ LUTS and sexual dysfunction have a substantial neg-
ative impact on a man’s quality of life and are considered
a serious socio-economic problem (4). The current thera-
pies for BPH/LUTS are associated with bothering sexual
side effects, however, differing in rate and characteristics
between different classes of medications, different medica-
tions within the same classes, and different combinations
of drugs (5). For these reasons, PDE5-Is are introduced in
the Italian pharmacopeia as an effective and treatment for
LUTS associated with ED. Even if PDE5-Is are effective
either alone or in combination with α-blockers in men
with BPH/LUTS, some adverse events, such as headache,
dyspepsia, and back pain, are commonly reported (5).
Furthermore, future studies are needed to evaluate the
long-term safety and efficacy outcomes and the overall
cost-effectiveness analysis of this treatment (5). On the
basis of the evidences, the use of phytotherapy in treating
lower urinary tract symptoms and benign prostatic hyper-
plasia has been popular in Europe for many years with
promising results. In the last years, the attention has been
focused on the both LUTS/BPH and ED treatment, due to
the patient’s request to improve his sexual and urinary
quality of life. Recently, the Alfa-5® association of Serenoa
repens, Pinus massoniana Bark Extract (PMBE) and Crocus
sativus, named IDIProst® Gold, has been produced in order
to improve the micturition parameters and sexual function
in patients affected by LUTS/BPH and ED. The effects on
micturition parameters are due to the effects of Serenoa
repens, as well known, and the effect on sexual function
has due to PMBE and Crocus sativus. We aimed to evalu-
ate the efficacy of the Alfa-5® association Serenoa repens,
PMBE and Crocus sativus (IDIProst® Gold) in improvement




All patients with clinical and instrumental diagnosis of
LUTS due to BPH and ED, attending 5 Italians Urological
Institutions from May to December 2012 were enrolled
in this prospective, multicentre, phase 3 study. 
All patients underwent clinical and instrumental exami-
nations and IPSS, IIEF-5 and SF-36 questionnaires. After
enrolment, all patients were assigned to receive oral cap-
sules of IDIProst® Gold (one capsule q24h) or Serenoa
repens 320 mg (one capsule q24h) for 3 months. The
main outcome measure was the improvement of quality
of life at the end of the whole study period, evaluated by
questionnaires results.
Inclusion and exclusion criteria
Patients were eligible for inclusion if they had to meet all
of the following criteria: age of 50 years or older; to be sex-
ually active; maximal urinary flow rate (Cmax) of less than
15 mL/s; post-residual voided volume less than 100 cc; an
International Prostate Symptom Score (IPSS) of 8 or greater
and an IPSS-quality of life (QOL) score of 2 or greater;
Prostate Specific Antigen (PSA) less than 4 ng/ml, or high-
er if negative prostate biopsy; an International Index of
Erectile Function (IIEF-5) score less than 21; to be untreat-
ed for LUTS/BPH; testosterone level more than 3 ng/dL.
We excluded all patients affected by major concomitant
diseases such as diabetes, liver, and/or renal failure; had
known anatomical abnormalities or malignancy of the uri-
nary tract, bladder, or upper tract stones, diverticula, for-
eign bodies, prostatitis, active urinary tract infection,
chronic retention or had polycystic kidney disease.
Moreover, we excluded all patients with urethral stenosis
interfering with the evaluation of voiding function;
patients with a history of transurethral resections of the
prostate (TURP), laser therapy, or thermotherapy.
Similarly, all patients who tested positive for Sexually
Transmitted Diseases such as Chlamydia trachomatis,
Ureaplasma urealyticum or Neisseria gonorrhoeae were
excluded. Moreover, all patients with allergy to one or
more compounds of IDIProst® Gold were also excluded.
All patients treated with PDE5-Is were excluded too.
Study and treatment schedule
On arrival at each Centre, all eligible individuals signed
written informed consent and underwent a baseline ques-
tionnaire, urological examination with anamnestic inter-
view and uroflowmetry (Cmax) with evaluation of post
voided residual volume (PVR), in accordance with the
procedure described in EAU guidelines (6). PSA value has
been previously evaluated. All patients who met the inclu-
sion criteria were assigned to groups according to a 1:1
randomization (Figure 1). 
Group A: IDIProst® Gold (one capsule q24h). 
Group B: Serenoa repens 320 mg (one capsule q24h). 
All patients underwent treatment for 3 months. All
patients were contacted by telephone on day 30 of the
therapy to ensure correct timing and dose treatment.
Each subject was scheduled for follow-up examination at
3 months from starting therapy, with a urological visit,
uroflowmetry with evaluation of PVR and questionnaires
to be filled in. No placebo arm was included. The possi-
ble biases caused by the lack of placebo arm were con-
sidered in the results analysis. The main outcome meas-
ure was the improvement of quality of life at the end of
the whole study period, in terms of changes in IPSS,
IPSS-QOL, Cmax, PVR, SF-36 and the IIEF-5 from base-
line to the evaluation point, that is, 3 months. Clinical
failure was defined as the persistence of symptoms after
the treatment, or the suspension of therapy for signifi-
cant reported adverse effects. In addition, spontaneously
reported adverse events, or those noted by the investiga-
tor, were recorded during the whole study period. 
The study was conducted in line with Good Clinical
Practice guidelines, with the ethical principles laid down in
the latest version of the Declaration of Helsinki.
Questionnaires and urological examinations
The validated Italian versions of the International Prostatic
Symptom Score (IPSS) (7), International Index of Erectile
Function (IIEF-5) (8) and SF-36 (9) were administered to
each patient. 
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The questionnaire was offered to the patient on arrival at
each Centre. All questionnaires were also used in deter-
mining clinical therapy efficacy.
Composition and characterisation of the extracts used
All patients assigned to Group A were orally adminis-
tered IDIProst® Gold once daily.
IDIProst® Gold
Each capsule (950 mg) contains the Alfa-5® association
consists of Serenoa repens 320 mg, Crocus sativus 100 mg,
Pinus massoniana 120 mg. All compound analyses were
carried out according to Fiamegoset et al. (10). All
patients assigned to Group B were orally administered
Serenoa repens 320 mg.
Statistical analysis
In order to analyse the homogeneity of the two groups,
the baseline characteristics were compared using the t test
and Wilcoxon-Mann-Whitney test for continuous vari-
ables and by the chi-square test for categorical variables.
The sample size was calculated prospectively under the
following conditions: difference between the groups =
10%, Alpha Error Level = 0.05 two-sided, statistical
power = 80% and anticipated effect size (Cohen’s d = 0.5).
The calculation yielded 2 × 64 individuals per group.
Analysis of variance (ANOVA) was used for comparing
means. Bonferroni adjustment test was also used at the
second stage of the analysis of variance. The effect size
between the means (Cohen's d) was also calculated. The
differences between the groups regarding semen parame-
ters were obtained using chi-square or Fisher’s exact tests.
Statistical significance was achieved when p was < 0.05. 
All reported p-values were two-sided. Statistical analyses
were performed using SPSS 11.0 for Apple-Macintosh
(SPSS, Inc., Chicago, Illinois).
RESULTS
From a total population of 146 patients with LUTS/BPH
and ED, 132 patients were eventually enrolled and ran-
domised. Out of the 14 patients excluded from the
study, 10 had refused to be enrolled and 4 were lost at
the follow-up. Finally, 132 were allocated (Figure 2). 
Anamnestic and clinical data at enrolment are described
in Table 1. No statistically significant differences
between the groups were found. From 132 enrolled
patients, 85 were allocated to IDIProst® Gold and 46 to
Serenoa repens 320 mg.
Compliance to treatment schedule and adverse effects
In Group A 83 patients (97.6%) were analysed after 2
were lost at follow up. In Group B 46 patients (97.8%)
were analysed after 1 was lost at follow up (Figure 2).
Accordingly, compliance to this study protocol was sat-
isfactory. The IDIProst® Gold formulation was well toler-
ated in all patients analysed and there were no significant
drug-related side effects. In Group A, 1 out of 83 patients
(1.2%) had mild adverse effects that did not require
treatment suspension. Also in Group B, 1 out of 46
patients (2.1%) reported mild adverse effects.
Clinical and laboratory results at follow up
At the follow-up examination (3 months after treatment),
statistically significant differences have been reported
between the two groups in terms of IPSS (11.9 vs 13.8;
df = 127; t = 10.3; p < 0.001), IIEF-5 and SF-36 mean
scores (19.3 vs 16.1; 99.7 vs 96.3; df = 127; t = 17.4;
p < 0.003; df = 127; t = 18.4; p < 0.001). Moreover, sta-
tistically significant differences were then reported
between the two visits, in terms of IIEF-5 and SF-36
scores (p < 0.001; p < 0.001), in the IDIProst® Gold
group. Very few AEs have been reported in the both
groups without any significant difference. 
Figure 1.
The figure shows the study design.
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The Table 2 shows all questionnaires results between the
two groups at the enrolment and at the follow-up visit.
DISCUSSION
LUTS due to BPH and sexual dysfunction are very com-
mon in men and the association between LUTS/BPH and
ED is very intriguing. Moreover, some epidemiological
studies demonstrated that the association between
LUTS/BPH and sexual dysfunction in ageing men is inde-
pendent of the effects of age, other comorbidities and
lifestyle factors (11). On the other hand, there is an
increasing needed for drugs able to improve the patient’s
quality of life without adverse side effects. In the present
study we evaluate the efficacy of IDIProst® Gold in
improvement of patient’s quality of life. We found some
important findings: 1) the efficacy of IDIProst® Gold in
improve urinary and sexual function in patients affected
by LUTS/BPH and ED, when compared with Serenoa
repens alone; 2) the improvement in sexual quality of life
is linked with an higher overall quality of life regardless
of the urinary function; 3) very few adverse side effects
have been found in the IDIProst® Gold group. 
The efficacy of IDIProst® Gold in the management of uri-
nary and sexual function is due to the association between
Serenoa repens, PMBE and Crocus sativus. Even if the effi-
cacy of Serenoa repens appears to be a useful option for
improving lower urinary tract symptoms (12), the associa-
tion with PMBE and Crocus sativus is able to improve the
efficacy of Serenoa repens due to: a) antioxidant effect, free
radical scavenging activities and vasoprotective effect due
to oligomeric proanthocyanidin complexes (OPC) of Pinus
massoniana Bark Extract (PMBE) (13-14), b) increasing of
nitric oxide activity by antioxidant effect of PMBE, c) apop-
tosis inducing properties of PMBE (15), d) promotion of
the diffusion of oxygen in tissues due to Crocus sativus
effect (16) and e) the aphrodisiac properties of Crocus
sativus (17). Recently, Hosseinzadeh et al. demonstrated in
an animal model study the aphrodisiac activity of Crocus
sativus aqueous extract and its constituent crocin (18). 
Moreover, they demonstrated that crocetin, a constituent
of saffron, significantly restored the endo thelium-de pen -
dent relaxation of the thoracic aorta in hypercholes-
terolemic rabbit, which might be explained by its action to
increase the vessel eNOS activity, leading to elevation of
NO production (18). 
Figure 2.
The figure shows the study flow-chart.
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The same authors highlighted that as crocin (the crocetin
digentiobiosyl-ester) converts to crocetin, it is possible
that this component acts in a way similar to PDE-5
inhibitors such as sildenafil (18). 
Furthermore, Crocus sativus seems to have affinity to bind
benzodiazepine receptors (19) and exhibited antidepres-
sant activity that it might inhibit the reuptake of sero-
tonin (20). 
Moreover, Shamsa et al. in a clinical trial found that after
the ten days of taking saffron there was a statistically sig-
nificant improvement in tip rigidity and tip tumescence as
well as base rigidity and base tumescence, highlighting
that Crocus sativus showed a positive effect on sexual func-
tion with increased number and duration of erectile events
seen in patients with ED even only after taking it for ten
days (21). 
These are the pharmacological basis justifying the effec-
tiveness of IDIProst® Gold. Another aspect to discuss is
the fact that we have found that an improvement in sex-
ual quality of life is linked with a higher overall quality
of life regardless of the urinary function. It could be due
to the fact that the impact of sexual dysfunction on pa -
tients’ quality of life is higher than LUTS, as demonstrat-
ed by several authors (3, 22.) 
Finally, the present study shows few limitations to take
into account; firstly, the lacks of placebo arm. 
However, we planned this study without a placebo arm
due to the fact that we think that is not ethical to not
treat patients with LUTS/BPH and ED. Moreover, the
short follow-up period that not allows to evaluate the
possible adverse side effect at long time.
IDIProst®Gold mean (SD or %) Serenoa repens 320 mg mean (SD or %)
Patients (n°) 83 46
Background information
• Age 58.9 (± 3.56) 59.1 (± 3.68)
• Marital status
Married 53 (63.8) 30 (65.3)
Unmarried 20 (24.0) 11 (23.9)
Divorced 10 (12.2) 5 (10.8)
• Educational qualification
Primary School 30 (36.2%) 18 (39.1%)
High School 29 (35.0%) 15 (32.7%)
University 24 (28.8%) 13 (28.2%)
• Smooking
Yes 28 (33.8) 16 (34.7)
No 55 (66.2) 30 (65.3)
• Comorbidity Charlson Index 1.9 (± 0.8) 2.0 (± 0.9)
• BMI (Body Mass Index) 26.9 (± 1.3) 27.1 (± 1.1)
Baseline clinical data
• PSA total (ng/mL) 2.02 (± 1.45) 2.08 (± 1.59)
• PVR (mL) 29.9 (± 28.8) 32.8 (± 29.9)
• Uroflowmetry data Qmax (mL/sec) 11.7 (± 2.2) 11.9 (± 2.1)
• Prostate volume (mL) 43.9 (± 21.1) 41.4 (± 17.2)
• IPSS 17.1 (± 5.9) 16.9 (± 5.8)
• IIEF-5 14.9 (± 3.5) 15.1 (± 3.7)
• SF-36 96.4 (± 1.1) 96.9 (± 1.2)
Table 1.
Clinical, instrumental and laboratory patient’s data.
IDIProst®Gold Serenoa repens 320 mg
mean (SD) mean (SD)
IPSS
v1 17.1 (± 5.9) 16.9 (± 5.8)
v2 11.9 (± 1.1) 13.8 (± 1.3)
IIEF-5
v1 14.9 (± 3.5) 15.1 (± 3.7)
v2 19.3 (± 1.0) 16.1 (±1.2)
SF-36
v1 96.4 (± 1.1) 96.9 (± 1.2)
v2 99.7 (± 1.2) 96.3 (± 2.3)
Table 2.
Questionnaires results at the enrolment and at the follow-up visit.
The table shows the anamnestic, clinical and instrumental data from all patients at the enrolment time. 
n° = number; SD or % = Standard Deviation or percentage; PVR = post-residual voided volume; IPSS = International Prostate Symptom Score; 
IIEF-5 = International Index of Erectile Function; SF-36 = Short Form-36.
The table shows all questionnaires results between the two groups at the
enrolment and at the follow-up visit. 
v1 = visit 1 (time 0); v2 = visit 2 (after 3 months). SD = Standard Deviation;
IPSS= International Prostate Symptom Score; IIEF-5 = International Index
of Erectile Function; SF-36 = Short Form-36
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CONCLUSION
In conclusions, we found that IDIProst® Gold significantly
improve the quality of life of patients affected by LUTS
due to BPH and ED, specifically in terms of sexual func-
tion, highlighting that a better sexual quality of life is cor-
related with an higher overall quality of life regardless of
the urinary function.
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